Sign In
Buy SPRY
$8.75
-0.150 (-1.69%)
At Close: Jun 03, 2026
ARS Pharmaceuticals Inc Is Under Investigation By The Schall Law Firm And Impacted Investors Are Encouraged To Begin Discussions
11:15pm, Tuesday, 13'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuti
ARS Pharmaceuticals Inc Is Under Investigation By The Schall Law Firm And Impacted Investors Are Encouraged To Initiate Dialogue
11:45pm, Monday, 12'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuti
ARS Pharmaceuticals, Inc. (SPRY) ARS Pharmaceuticals neffy (epinephrine nasal spray) FDA Approval Conference Call Transcript
11:26am, Monday, 12'th Aug 2024
ARS Pharmaceuticals, Inc. (SPRY) ARS Pharmaceuticals neffy (epinephrine nasal spray) FDA Approval Conference Call Transcript
5 Stocks Under $10 Growing 50% Or More
10:13am, Sunday, 11'th Aug 2024
Are you looking for low-cost stocks to add to your portfolio?
ARS Pharmaceuticals Inc Is Under The Schall Law Firm's Probe And Affected Investors Are Encouraged To Begin Conversations
07:00pm, Friday, 09'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceutic
Nasal spray alternative to EpiPen for allergic reactions approved by FDA
04:24pm, Friday, 09'th Aug 2024
Neffy is expected to be available in the United States within eight weeks of FDA approval, the company said.
neffy Offers Adults and Children (≥30 kg) Living with Severe Allergic Reactions the First New Delivery Method for Epinephrine in more than 35 Years
US FDA approves first nasal spray for allergic reactions
11:36am, Friday, 09'th Aug 2024
The U.S. Food and Drug Administration said on Friday it had approved ARS Pharmaceuticals' nasal spray as the first needle-free emergency treatment for potentially fatal allergic reactions.
ARS Pharmaceuticals Inc Is Being Investigated By The Schall Law Firm And Impacted Investors Are Urged To Initiate Dialogue
07:45pm, Thursday, 08'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceutic
ARS Pharmaceuticals Inc Is Under Investigation By The Schall Law Firm, And Impacted Investors Are Encouraged To Initiate Dialogue
06:45pm, Wednesday, 07'th Aug 2024
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY)
ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference
09:01am, Wednesday, 07'th Aug 2024
SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Lags Revenue Estimates
06:21pm, Tuesday, 06'th Aug 2024
ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.18 per share a year ago.
ARS Pharmaceuticals Inc Investigated By The Schall Law Firm And Impacted Investors Urged To Engage In Dialogue
05:45pm, Tuesday, 06'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceutic
ARS Pharmaceuticals Provides Business Highlights and Reports Second Quarter 2024 Financial Results
04:01pm, Tuesday, 06'th Aug 2024
neffy ® (epinephrine nasal spray) New Drug Application (NDA) under review by FDA; discussions are ongoing to finalize labeling with FDA; PDUFA date in early October 2024
ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
11:05am, Thursday, 01'st Aug 2024
ARS Pharmaceuticals, Inc. (SPRY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
